Generics don’t get an easy ride in Canada As brand-name producers push for longer data exclusivity and a better appeals process in Canada, Jim Keon, president of the Canadian Generic Pharmaceutical Association, explains the misconceptions about Canadian regulation to Alli Pyrah
The healthcare system needs stronger IP protection Declan Hamill, chief of staff and vice president (legal affairs) for Rx&D tells James Nurton why the innovative life sciences industry has concerns about the lack of patent term restoration, utility standards and access to medicines
Canada’s new Combatting Counterfeit Products Act Cynthia Rowden of Bereskin & Parr explains recent legislation that offers better counterfeiting remedies and streamlines registration procedures
How the Amazon ruling affected business-method patents Matthew Zischka and Colin Ingram of Smart & Biggar analyse decisions on computer-implemented inventions, alongside CIPO’s efforts to strengthen and clarify policy
